 Connection
Marc Bonaca to Hospitalization
This is a "connection" page, showing publications Marc Bonaca has written about Hospitalization.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.564 |
|
|
|
-
Gluckman TJ, Chiu ST, Rider D, Tseng PK, Mudd JO, Remick JD, Granowitz C, Carroll A, Sikirica S, Canonico ME, Hsia J, Bonaca MP. Relationship Between Left Ventricular Ejection Fraction and ICD-10 Codes Among Patients Hospitalized With Heart Failure. Clin Cardiol. 2024 12; 47(12):e70055.
Score: 0.416
-
Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J. 2021 05; 235:12-23.
Score: 0.319
-
Canonico ME, Hsia J, Chiu ST, Tseng PK, Mudd JO, Remick JD, Patel B, Chuang YH, Gluckman TJ, Bonaca MP. Temporal shift in prevalence of heart failure diagnoses and comorbidities within 2 US integrated health systems. Am J Manag Care. 2025 Aug 01; 31(8):e238-e240.
Score: 0.109
-
Scimeca G, Krishnathasan D, Rashedi S, Lan Z, Sato A, Hamade N, Bejjani A, Khairani CD, Davies J, Porio N, Assi AA, Armero A, Tristani A, Ortiz-Rios MD, Nauffal V, Almarzooq Z, Wei E, Zuluaga-Sánchez V, Zarghami M, Achanta A, Jesudasen SJ, Tiu B, Merli GJ, Leiva O, Fanikos J, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll B, Goldhaber SZ, Campia U, Bikdeli B, Piazza G. Predictors of venous thromboembolic events in hospitalized patients with COVID-19. J Thromb Thrombolysis. 2025 Apr; 58(4):485-496.
Score: 0.106
-
Hsia J, Spyropoulos AC, Piazza G, Weng S, Dunne MW, Lipardi C, Barnathan ES, Bonaca MP. Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thromb Haemost. 2024 Jul; 124(7):649-655.
Score: 0.097
-
Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial. Clin Cardiol. 2023 03; 46(3):348-349.
Score: 0.091
-
Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. Clin Cardiol. 2022 Aug; 45(8):831-838.
Score: 0.088
-
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 05 28; 139(22):2516-2527.
Score: 0.070
-
Roetker NS, Victores A, Kou C, Bash LD, Ramey DR, Ke X, Bonaca MP, Wetmore JB. Health care resource utilization and costs of major bleeding in patients with and without dialysis-dependent end-stage kidney disease: a retrospective study. Res Pract Thromb Haemost. 2026 Mar; 10(3):103437.
Score: 0.028
-
Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Eur Heart J. 2026 Feb 11; 47(6):683-697.
Score: 0.028
-
Bikdeli B, Krishnathasan D, Bejjani A, Khairani CD, Hamade N, Campia U, Davies J, Porio N, Assi A, Armero A, Tristani A, Ortiz-Rios MD, Nauffal V, Almarzooq ZI, Wei EQ, McGonagle B, Pfeferman M, Rashedi S, Sato A, Scimeca G, Zuluaga-Sánchez V, Zarghami M, Achanta A, Jesudasen S, Tiu BC, Merli GJ, Leiva O, Fanikos J, Sharma AM, Rizzo SM, Morrison RB, Vishnevsky A, Rao SJ, Naveh S, El Rafei A, Welker J, Bonaca MP, Carroll BJ, Goldhaber SZ, Lan Z, Piazza G. Adjudicated Cardiovascular Events in Patients With COVID-19: Association With Vaccination Status and Changes over Time. J Am Heart Assoc. 2025 Dec 16; 14(24):e044011.
Score: 0.028
-
Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025 Sep 27; 406(10510):1351-1362.
Score: 0.027
-
Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Felker GM, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, She L, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2025 Sep 27; 406(10510):1341-1350.
Score: 0.027
-
Zannad F, Reddy YNV, Barash I, Anstrom KJ, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor CM, Ponikowski P, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Butler J. Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR. J Am Coll Cardiol. 2025 Dec 16; 86(24):2471-2491.
Score: 0.027
-
Reddy YNV, Butler J, Anstrom KJ, Blaustein RO, Bonaca MP, Corda S, Ezekowitz JA, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Patel M, Ponikowski P, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial. Eur J Heart Fail. 2025 Feb; 27(2):209-218.
Score: 0.026
-
Piazza G, Spyropoulos AC, Hsia J, Goldin M, Towner WJ, Go AS, Bull TM, Weng S, Lipardi C, Barnathan ES, Bonaca MP. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. Circulation. 2023 06 20; 147(25):1891-1901.
Score: 0.023
-
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
Score: 0.021
-
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 01 24; 380(4):347-357.
Score: 0.017
-
O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1591-9.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|